HappyLibrarian,
The bottleneck for personalized commercial scale medicine has always been manufacturing because of cost to produce manually any broad scale application of a medicine, especially one that has tissue and indication agnostic possibilities written into actual function. Investors aren’t looking to invest in something that leads to “dead money” during development of something as complex as L and its manufacturing so it takes a special kind of supporting cast to get from concept to practical application in a commercial scale setting. The bears know this which is why they discredit and mock those who have been long term supporters. The time element involved with development makes this a good strategy most of the time for price suppression and a push for bankruptcy which is why those with such intentions have participated in this with impunity. Time simply runs out as financing becomes more and more difficult and in the past there has not been enough money or wherewithal to make a successful challenge against this practice.
Manufacturing news is where the share price surges bridled only by the rate capacity can be increased. Until then it’s just one more step towards that day but some steps will be bigger than others. Times they are a changing!; ). Best wishes.
Market Data 
Markets 
AI
